Our commitment

As a leader in orthopaedic innovation, Corin has pioneered a number of landmark orthopaedic developments since it was founded in 1985. We are very proud that we have been able to improve the quality of life of hundreds of thousands of patients across the world through the introduction of these ground breaking products, and believe this heritage distinguishes Corin within the global orthopaedic market. Our talented and dedicated teams continue to share a common commitment delivering quality orthopaedic products and services to patients, surgeons and healthcare providers, which exceed their expectations and positively impact their lives, through Responsible Innovation. This is the cornerstone of everything we do.

Our values
Quality focus
Ensuring quality is the primary core value across the business.

Technical excellence
Building and developing talented teams who are experts in their eld.

Creative enthusiasm
Empowering individuals to seek innovative solutions and continuous improvements.

Responsive support
Responding quickly and resourcefully to our internal and external customers.

Positive impact
Making a real difference and inuencing positive change for patients, surgeons, healthcare providers and our company.

Responsible Innovation

Our experience
Corin is a world leader in the development, production and distribution of a wide range of cutting edge, reconstructive orthopaedic devices. We are committed to nding new and innovative solutions to positively impact the lives of patients around the globe.
At the forefront of modern generation metalon-metal hip resurfacing in the early 1990s, thousands of young, active patients, previously offered no surgical solution, are now benetting from Corins Cormet hip resurfacing device. Rotaglide+, the worlds rst true mobile bearing total knee replacement, has also played an important role in enabling large numbers of patients to return to increased levels of mobility and activity. Utilising our in-house knowledge and experience, coupled with the know-how of eminent surgeons, Corin has now broadened its innovative product offering which today includes a wide range of cutting-edge brands. Alongside Cormet, our hip continuum of care also encompasses Trinity advanced bearing acetabular system, ECiMa next generation vitamin E technology, MiniHip bone conserving stem and MetaFix, TaperFit and CTi II total hip stems. Rotaglide+ total knee and Uniglide unicompartmental knee are being joined by Unity Knee, a new fth generation total knee system. Within our wider product portfolio and further extending our range of advanced treatment options, Zenith total ankle replacement and LARS soft tissue internal xation also play an important role in bringing quality of life to patients. The growing proportion of people undergoing joint replacement from the ageing population, combined with increased expectations for an active lifestyle, mean that demand for new, innovative and durable products remains high. With a reputation for breaking new ground, Corins commitment to restoring quality of life remains strong, through continued investment in new technologies and new product development.

4 |

Our focus
With advances in healthcare across the globe and higher expectations for a sustained quality of life well into old age, the world is seeing an ageing, more active population. This in turn is driving growth in the international orthopaedic market as the demand for procedures increases. In order to support patients and healthcare professionals around the world, our strategy is focused on the following areas:

Broaden Innovate

Extending our hip and knee portfolio

Developing new implant solutions

Strengthen

Increasing our global sales presence

Responsible Innovation | 5

Our geography
Corin has direct operations in six of the worlds major orthopaedic markets, with distribution arrangements in over 30 other countries. Corin subsidiaries Australia Austria Germany Japan United Kingdom United States Global partners Argentina Belgium Bolivia Brazil Canada China Colombia Costa Rica Croatia Cyprus Czech Republic Ecuador Egypt Greece India Israel Italy Korea Lebanon Malaysia Malta Mexico Netherlands Pakistan Poland Portugal South Africa Spain Sri Lanka Sweden Thailand Turkey United Arab Emirates Venezuela

6 |

Responsible Innovation | 7

Our history
Since its foundation in 1985, Corin has grown from a small UK orthopaedic business to a global orthopaedic solutions provider with operations in 40 countries worldwide. Throughout this rapid growth phase Corin has established a strong presence across key orthopaedic segments, providing innovative and unique solutions to longstanding patient complications and challenges. In 2008, a new senior management team instigated a ve year strategic plan initiating major investment into new product development. Since this time Corin has seen approvals for its new continuum of care portfolio in most leading global markets, including the US, Europe, South America and Australia, along with world leading technology launches such as ECiMa advanced bearing technology, allowing better treatment options for active patients.

Corin is founded in Cirencester, UK, deriving its name from the towns name in Roman Britain, Corinium.

Corin USA established.

1992

Corin McMinn hip resurfacing is launched.

Corin Japan established.

1985

1989

1997

1989

1995

1997

Rotaglide

knee system is launched rst true meniscal bearing knee system on the market.

TaperFit

cemented hip system is launched.

Cormet

hip resurfacing is launched.

8 |

Corin oats on the London Stock Exchange. Corin acquires Alphanorm (later to become Corin Germany) to gain presence in the German and Austrian markets.

Corin Australia established.

2002

2004

Corin achieves sales in excess of 20m.

FDA approval for Cormet in the USA.

New senior management team embark on renewed ve year strategic plan with major investment in new product development. Corin expands UK headquarters to new site.

Corin achieves sales in excess of 40m.

Collaboration with a leading research institute to develop ECiMa next-generation vitamin E technology. Global supply agreement signed with MAKO Surgical Corp, to provide total hip solutions for the Rio interactive robotic system.

2003

2007

2008

2009

2010

2002

2008

2009

2010

2012

Uniglide AMC

MetaFix Zenith

MiniHip

New knee products are introduced through Alphanorm acquisition.

cementless hip and total ankle system are launched.

bone conserving hip system is launched rst true conservative hip option based on global demographics.

Trinity

advanced bearing acetabular cup system is launched.

Unity Knee

the worlds rst fth generation knee system providing a true system approach and active patient kinematics.

Responsible Innovation | 9

Our hip portfolio

Todays patients expect, and deserve, to have access to the very latest treatment options. With a global population that is living longer and becoming more active, the need to ensure conservative and effective treatment pathways has never been more important. Corins hip continuum of care ensures each patient receives the optimal patient matched solution, using some of the most advanced bearing technologies in the world.

Cormet

Advanced Hip Resurfacing System

MiniHip

Bone Conserving Hip Replacement

MetaFix TaperFit Trinity

10 |

Cementless Total Hip Replacement

Cemented Total Hip Replacement

Advanced Bearing Acetabular System

Responsible Innovation | 11

Our knee portfolio

Corin has long established its credentials in providing unique world class knee solutions, with the worlds rst truly mobile knee system, Rotaglide+, and one of the most advanced mobile and xed bearing unicompartmental knee offerings, Uniglide. Unity Knee brings a new dimension to patients and surgeons, helping them address the long-standing issues relating to patient satisfaction and wear through a high performance, intelligent knee platform based on modern day knee kinematic principles.

Uniglide

Unicompartmental Knee Replacement

Unity Knee Rotaglide+

Total Knee System

Fifth Generation Knee System

AMC II

Total Knee System

12 |

Our wider portfolio

Zenith is one of the most advanced total ankle replacements of its kind, providing a high performance alternative to ankle fusion. Together with an innovative implant design concept, advanced material technology and state of the art instrumentation, Zenith is rapidly restoring condence in total ankle surgery. LARS is one of the worlds most advanced non-biological soft tissue treatment options providing a high performance alternative to harvesting existing soft tissues.

Zenith LARS

Total Ankle Replacement

Soft Tissue Internal Fixation

Solomax

Pulsed Lavage System

Responsible Innovation | 13

Our technology
Corin has developed a worldwide network of research associations with leading universities, research institutes and industrial partners, ensuring that we stay at the forefront of innovation.
State of the art test methodologies are used to develop and verify new technologies to demonstrate the safety and efcacy of all our prostheses. Advanced computer simulation technologies model and predict the lifecycle of prostheses, whilst kinematic analysis and mechanical simulations are used to replicate patients behaviour, ensuring that product performance is optimised over the life of the implant. Research into new materials allows us to offer world-rst technologies for the next decade through developing products based on the very best in implant technology, designed to enhance longevity and performance. The focus of research concentrates on providing patient benets to improve quality of life in a society of increasingly active arthritic patients minimising wear, addressing aseptic loosening and reducing stress shielding that can cause bone loss around implants and increased revision rates. Corin has a rst class track record of gaining access to external grant funding (Technology Strategy Board, NIHR i4i and EU funding) and running multi-discliplinary research projects with a clear end goal to develop products for improved patient function and benet. Research outputs are disseminated at international conferences and via publications in peer-reviewed journals in collaboration with our global research partners and key opinion leaders.

14 |

ECiMa
In a unique collaboration, Corin has worked with a leading research institute on the development and commercialisation of a next generation vitamin E polyethylene. The result, ECiMa, is a cold-irradiated, mechanically-annealed, vitamin E-blended ultra high molecular weight polyethylene (UHMWPE). The most advanced polyethylene of its kind, ECiMa has been developed to minimise wear, improve oxidation resistance in todays increasingly younger and more active patients, and to offer mechanical properties superior to other conventional highly cross-linked polyethylenes due to its unique process.

Global collaboration
Corin is engaged in world-class collaborations with global innovation leaders in the pursuit of the forgotten implant an implant offering such performance that the patient forgets its presence. Next generation porous implants with enhanced xation and bone adaptive structures that minimise stress shielding are being specically developed for the increasingly younger and more active demographic. Such implants have optimised micro-textured surfaces to improve initial stability and secure rapid osseointegration. The forgotten implant will offer increased functionality and longevity, and as research continues will represent the next major advancement in implant technology.
Responsible Innovation | 15

16 |

Our operation
An example of British manufacturing success, all production takes place on-site at our UK headquarters. Our facilities have consistently been updated over the years to encompass the very latest manufacturing technologies and modern production principles, ensuring all Corin products meet the very highest standards in quality engineering.
The combination of modern manufacturing methodologies alongside continued investment in high tech computer-controlled machinery ensures the highest level of operational efciency. This enables us to produce quality products, ensuring the best patient outcomes for our global operating partners. Corin operates in a highly regulated environment with frequent and thorough external quality audits to ensure our continuing compliance with relevant statutory and industry standards. All products are designed to be safe and reliable and comply with, or exceed, all legal and regulatory requirements. Quality is a core value deeply embedded within Corins culture across all aspects of the organisation and every product is subject to the highest level of quality assurance. Today, computer aided technology is central to all aspects of our business, from the creation of the initial concept ideas through to the manufacture and measurement of all components using computer-controlled coordinate measuring machines (CMMs) and high-end vision systems. Coupled with this quality and technology is a highly skilled and motivated workforce. Our teams combine experienced individuals who have been in medical manufacturing for many years, with the ongoing development of the best local talent through an effective and well-established apprenticeship programme, developed in conjunction with a local university. We have a strong environmental, health and safety awareness across all areas of our business, anticipating future requirements so that the health and safety of customers and patients is continually enhanced. In an ever-competitive market, the culture within Corin encourages people at all levels to engage in an environment of continuous improvement, positively impacting on the growth and development of Corin.

Responsible Innovation

17

Our support
Corin Academy was established to provide a wide range of surgeon training initiatives to meet the needs of the changing global orthopaedic community.
Through a range of meeting and education formats, our vision is to provide a forum to debate and discuss current concepts and best practice in orthopaedic surgery, and to help build long-term clinical success for todays patient population. We deliver this through the following initiatives:

The Experience
Live surgery

The Masterclass
Expert guidance

The Forum
Sharing best practice

The Science
Surgeon-led congress

The Lab
Cadaveric workshops

18 |

Surgeon to surgeon visits

Utilising the most highly-skilled practitioners to train surgeons on each procedure ensures that best practice is passed on, enabling excellent clinical performance and promoting long-term patient wellbeing as well as outstanding clinical results for Corin manufactured products. Surgeon to surgeon hospital visits offer highly effective one-on-one training opportunities allowing experts to discuss products which are at the foreground of modern orthopaedic practice. These exchanges facilitate opportunities for knowledge transfer in a live theatre environment.

The Experience meeting

Scientic congresses
Modern orthopaedic medicine depends on a lively interaction between experts in this ever-changing eld. In order to promote such discussion, Corin works diligently with a wide faculty of experts who are able to work with us to put together the most interesting and topical agendas and debates, whilst seeking to drive understanding and illuminate those areas requiring clarity. Through this close interaction with experts, Corin has been able to stay at the cutting edge of orthopaedic practice, to better understand the needs of surgeons and their patients.

Each year, the Corin Academy meeting calendar includes the successful Experience series. Through recognising the importance of a wide range of inputs and utilising these, we are able to make rapid progress with delegates and help them to greatly improve their understanding of products and procedures in a well-controlled environment. By using an innovative mixture of live video-link surgery, didactic sessions and dry-bone workshops, as well as interactive sessions such as difcult cases and what would you do?, delegates feel that they are able to get the best out of meetings and the valuable time away from their practices.

Responsible Innovation | 19

20 |

Our service
JointResponse provides a wide range of innovative reconstructive orthopaedic solutions on a short-term loan basis, working with client hospitals to help them meet their commitments to patients.
Corins highly trained and professional JointResponse customer support team works in partnership with client hospitals to understand requirements, delivering a personal level of service to meet the exact needs of all our individual customers. Implants spanning a range of sizes and associated instrumentation are dispatched to the hospital for the duration of surgery and then returned back to Corin. Loan kits are sent out on a guaranteed next morning delivery or they can also be fast-tracked for more urgent requirements. Instrumentation is maintained to the highest standard and supplied in high quality, custombuilt ight cases. Our comprehensive storage system and excellent cleaning facilities ensure that all orders are serviced promptly and accurately. All loan kits are supplied fullyfunctional and decontaminated. We know how important it is that the right implants, together with the right instrumentation, are delivered at exactly the right time. With a wealth of experience, the dedicated inhouse JointResponse team understands the importance of peace of mind. Whenever an order is placed with one of our friendly and helpful members, you can be assured of a fast, efcient and reliable response.

Responsible Innovation | 21

Our clinical responsibility

As an organisation, Corin places a great deal of importance on collaboration with key clinical institutions to deliver strong medical research programmes that support the safe and effective use of Corin implants.
Being at the cutting edge of new product development and also with well-established products in our portfolio, Corin has the dual responsibility of dealing with new product introductions as well as the changing face of the global regulatory systems relating to in-market devices. Taking our responsibility for patient wellbeing seriously means investing signicantly in short, medium and long-term studies of up to 15 years duration. As a company we support registries both locally and globally as well as single and multi-centre, international data collections, in order to ensure the safe and effective use of our devices worldwide. Over recent years we have implemented a dramatic increase in the level of clinical research activity carried out in relation to Corins devices. This has been driven by regulatory imperatives and the requirement to support the launch of a series of new hip products through global multi-centre initiatives. As we drive forward, we will continue to develop innovative products in a responsible manner. Our dedication to clinical data collection is strongly aligned to our enthusiasm for surgeon training, for it can only be by the combination of these two key elements that we will be able to produce long-term clinical efcacy and patient satisfaction. Corin will continue to invest signicantly in robust clinical research in partnership with leading global clinical centres to ensure the very best outcomes for our surgeons and their patients.

22 |

Responsible Innovation | 23

24 |

Our corporate responsibility

Corin is committed to carrying out its operations in a socially and environmentally responsible way. In all aspects of our operations and dealings with customers, business partners, employees, shareholders and the local community, we recognise the importance of corporate responsibility both to our stakeholders and to the long-term success of our business.
Our responsibilities to our customers are of paramount importance as we continue to develop and expand our range of products. We provide education and training support for healthcare professionals and maintain a signicant investment in research and development. Our products are designed to be safe and reliable, complying with or exceeding all legal and regulatory requirements. Corin has a formal code of conduct providing guidelines for employees regarding business behaviour, interactions with healthcare professionals, conicts of interest and the use of intellectual property, information and company resources. We offer employees the encouragement to learn and progress, fairly recognising and rewarding performance. Our recruitment and promotion policies are based solely on qualications and abilities and we do not tolerate discrimination on any grounds. All operations are conducted in accordance with generally accepted principles and rules of good governance and we aim to provide sustained, protable growth to our shareholders, valuing their views and recognising their interest in the Groups strategy and performance. We provide regular information on our activities, structure, nancial situation and performance. Corin considers that making a contribution to the communities in which we are based is an important commitment and we support employees who undertake voluntary or community work. We contribute to a number of charitable causes each year, focusing on the provision and promotion of health and welfare services both within the local community and further aeld in some of the worlds less developed countries.
Responsible Innovation

Environmentally we recognise the need to protect and preserve the worlds resources and accept our obligations as an organisation to identify and, as far as practicable, to reduce, re-use and recycle any aspect of our activities, products and services that could potentially have an adverse environmental impact. We are committed to comply with all applicable environmental legislation and actively maintain an environmental management system which meets the requirements of ISO 14001.

25

Our future
Through sustained investment in our core values, Corin continues to bring benets to hundreds of thousands of people, delivering on our commitment to provide treatment options that exceed the expectations and positively impact the lives of patients, surgeons and healthcare providers around the world. Responsible Innovation is the cornerstone of everything we do and drives our vision and dedication to become one of the most respected orthopaedic medical device companies in the world.

26 |

The Corinium Centre Cirencester, GL7 1YJ United Kingdom t: +44 (0)1285 659 866 f: +44 (0)1285 658 960 e: info@coringroup.com

www.coringroup.com
This document has been printed in the UK on Novatech Matt paper which is sourced from FSC Chain of Custody responsibly managed forests. The paper is produced at a mill which holds certications for ISO 9001 Quality Management System, ISO 14001 Environmental Management Standard and the Carbon Trust Standard. The pulp is bleached using Elemental Chlorine Free processes. If you have nished reading this report and no longer wish to retain it, please pass it on to other interested readers; return it to Corin or dispose of it in your recycled paper waste. Thank you.

Responsible Innovation

2012 Corin P No. I1187 Rev0 01/2012 ECR 11593

Responsible Innovation